Ockham Research Staff @ July 25, 2008 # No Comment Yet
Biotechnology powerhouse Amgen, Inc. (AMGN) has seen its stock price appreciate over 16% year-to-date in what has otherwise been an abysmal market. Despite the run-up in AMGN shares, Ockham Research still finds the shares a compelling investment.
admin @ February 29, 2008 # No Comment Yet
The Ockham Research coverage universe, which includes nearly 3000 stocks, is chock full of attractively valued stocks right now. Earlier this month we reached over 90% buy recommendations, which is the most bullish we have been since we very nearly called the bottom after the internet bubble burst in 2002. […]
admin @ February 4, 2008 # No Comment Yet
It was a relatively slow day for news coming out of the markets, and there is about as much coverage of Super Bowl commercials as anything else. Perhaps Wall Street is a little slow in recovering from a night of partying after the New York Giants pulled off the stunning upset […]